G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
95 hedge funds and large institutions have $1B invested in G1 Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 18 reducing their positions, and 20 closing their positions.
144% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 18
35% more capital invested
Capital invested by funds: $741M → $1B (+$263M)
8.82% more ownership
Funds ownership: 61.77% → 70.59% (+8.8%)
1% more funds holding
Funds holding: 94 → 95 (+1)
5% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 20
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$50.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$30.9M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$23.1M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$19M |
| 5 |
BlackRock
New York
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$24.5M |
| 2 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$10.2M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$8.4M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$5.56M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.42M |
GTHX Hedge Fund Activity: Q2 2018 in Review
95 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q2 2018, worth a combined $1B — up 35% from $741M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new GTHX positions and 20 closed out — a net gain of 1 holder — while 44 added to existing stakes and 18 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $50.7M. The largest seller was Boxer Capital, exiting entirely with an estimated $24.5M sold.
- 95 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q2 2018, up from 94 in Q1 2018.
- Funds reported $1B of G1 Therapeutics, Inc. Common Stock stock for Q2 2018, up 35% quarter-over-quarter.
- 21 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q2 2018 and 20 closed out, a net change of +1 holder.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q2 2018 was Bank of New York Mellon, an estimated $50.7M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q2 2018 was Boxer Capital, an estimated $24.5M sold.
Based on aggregated 13F filings for Q2 2018.